Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Novo Nordisk’s purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. They do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases they treat. Novo Nordisk employs more than 55,000 people in 80 offices around the world, and markets their products in 170 countries. For more than 100 years, they have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like their insulin pens. Novo Nordisk’s treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From their labs to their factory floors, Novo Nordisk is discovering and developing innovative biological medicines and making them accessible to patients throughout the world.